Abstract: The present embodiment provides a compound represented by the formula (1): Q-CHR2??(1) (Q is a nitrogen-containing aliphatic group containing two or more tertiary nitrogens but no oxygen, and R is an aliphatic group containing a biodegradable group). From the compound in combination with other lipids such as a lipid capable of reducing aggregation, lipid particles can be formed. Further, the compound can be used for a pharmaceutical composition to deliver an activator into cells.

Abstract: According to one embodiment, a flow channel structure may include a first flow channel, and a second flow channel that joins the first flow channel. An end of the second flow channel close to the first flow channel has a first region having a depth shallower than a depth of the first flow channel.

Abstract: A flow channel structure for removing a foreign substance, including a first flow channel, where the first flow channel has a first region having a depth shallower than a depth of another region. A method for removing a foreign substance in a fluid, including flowing the fluid to the first flow channel of the flow channel structure for removing a foreign substance.

Abstract: According to one embodiment, a method for manufacturing a lipid particle including a drug, the method includes cooling a solution containing the lipid particle including the drug at a rate of less than or equal to 1° C. per minute.

Abstract: According to one embodiment, a vector set includes a first vector and a second vector. The first vector includes a transposase target sequence, a first promoter sequence ligated to downstream of the transposase target sequence, and a first reporter gene ligated to downstream of the first promoter sequence. The second vector includes a 5?-side transposase recognition sequence, a 3?-side transposase recognition sequence, and a first enhancer sequence arranged therebetween.

Abstract: The present embodiment provides a compound represented by the formula (1): Q-CHR2??(1) (Q is a nitrogen-containing aliphatic group containing two or more tertiary nitrogens but no oxygen, and R is an aliphatic group containing a biodegradable group). From the compound in combination with other lipids such as a lipid capable of reducing aggregation, lipid particles can be formed. Further, the compound can be used for a pharmaceutical composition to deliver an activator into cells.

Abstract: According to one embodiment, a set of nucleic acid constructs which detects a DNA homologous recombination deficiency includes a first nucleic acid construct and a second nucleic acid construct. The first nucleic acid construct includes a first promoter sequence and a cleaved Cre gene ligated to downstream of the first promoter sequence. The second nucleic acid construct includes a second promoter sequence, a first loxP sequence ligated to downstream of the second promoter sequence, a reporter gene ligated to downstream of the first loxP sequence, and a second loxP sequence ligated to downstream of the reporter gene.

Abstract: According to one embodiment, a substance delivery carrier and a composition are used for delivering an intended substance to a myeloid tumor cell. The substance delivery carrier has a lipid particle, and an intended substance encapsulated in the lipid particle. The lipid particle contains, as a constituent thereof, at least a first lipid represented by formula (I).

Abstract: The present embodiment provides a compound represented by the formula (1): Q-CHR2??(1) (Q is a nitrogen-containing aliphatic group containing two or more tertiary nitrogens but no oxygen, and R is an aliphatic group containing a biodegradable group). From the compound in combination with other lipids such as a lipid capable of reducing aggregation, lipid particles can be formed. Further, the compound can be used for a pharmaceutical composition to deliver an activator into cells.

Abstract: According to one embodiment, a nucleic acid construct is used for detecting an estrogen-sensitive cell. The nucleic acid construct includes an enhancer sequence, a promoter sequence and a reporter gene. The enhancer sequence includes at least an ERE sequence and at least a XRE sequence. The promoter sequence is ligated to downstream of the enhancer sequence. The reporter gene is ligated to downstream of the promoter sequence.

Abstract: According to one embodiment, a modified piggyBac transposase polypeptide includes a piggyBac transposase amino acid sequence and a nuclear localization signal amino acid sequence.

Abstract: According to one embodiment, a composition is for delivering an objective substance to the T-cell malignant tumor cell. The composition contains a substance delivery carrier. The substance delivery carrier has a lipid particle, and the objective substance encapsulated in the lipid particle. The lipid particle contains, as constituents thereof, at least a first lipid represented by formula (I) and a second lipid represented by formula (II).

Abstract: According to one embodiment, a method for determining a characteristic of a tumor cell group, the method includes bringing a lipid particle including a lipid membrane and a first nucleic acid included in the lipid membrane into contact with the tumor cell group (the first nucleic acid including a promoter sequence of a marker gene for determining the characteristic and a reporter gene linked to a downstream of the promoter sequence to be functionable), culturing the tumor cell group, detecting the presence or absence or an amount of a signal from a reporter protein that is expressed from the reporter gene, in each tumor cell included in the tumor cell group, and counting the number of tumor cells having the characteristic that is measured from a result of the detecting.

Abstract: According to one embodiment, there is provided a method of producing a gene modification T cell (CAR-T cells) which expresses a chimeric antigen receptor (CAR). This method includes stimulating a cell population containing a T cell with an antibody which activates the T cell, bringing the cell population into contact with a nucleic acid-introducing carrier, wherein the nucleic acid-introducing carrier containing a lipid particle, a first nucleic acid and containing a CAR gene, and a second nucleic acid containing a transposase gene encapsulated in the lipid particle, and culturing the cell population after the contacting.

Abstract: According to one embodiment, a nucleic acid delivery carrier is used to integrate a first sequence into a genome of cells. The nucleic acid delivery carrier includes a donor DNA containing the first sequence, an RNA agent containing at least an RNA encoding a protein involving integration of the first sequence into the genome, and a lipid particle encapsulating the donor DNA and the RNA agent.

Abstract: An analysis method is for determining an abundance ratio of first lipid particles containing an objective substance in a lipid particle group. The analysis method includes irradiating a solution including the lipid particle group with light, measuring at least two of the total number of the plurality of lipid particles, the number of the first lipid particles, and the number of second lipid particles not containing the objective substance in the solution by detecting scattered light, and calculating an abundance ratio of the first lipid particles.

Abstract: According to one embodiment, an examination device includes a reagent, a sheet and a detection unit. The reagent reacts with a measurement target and thereby causes light emission. The sheet is capable of adsorbing the reagent and gradually releasing the adsorbed reagent. The detection unit detects optical characteristics of the light emission caused by the reaction between the measurement target and the reagent.

Abstract: [Problem] To provide a biodegradable compound having a structure decomposed in a cell, lipid particles containing the compound, and a pharmaceutical composition comprising the lipid particles. [Solution] The compound of the embodiment is represented by the formula (1): P—[X—R—Y—R?-Q]2 (1). In the formula, P is an alkyleneoxy having an ether bond, X is a divalent linking group having a tertiary amine structure, R is a divalent linking group, R? is a single bond or a C1 to C6 alkylene, and Q is a liposoluble vitamin residue, a sterol residue, or a C12 to C22 aliphatic hydrocarbon group. The structure of the compound contains at least one biodegradable group. From the compound in combination with other lipids such as a lipid capable of reducing aggregation, lipid particles can be formed. Further, the compound can be used for a pharmaceutical composition to deliver an activator into cells.

Abstract: According to one embodiment, a nucleic acid condensing peptide includes one terminal having a first sequence RRRRRR and another terminal having a second sequence RQRQR. Between the first sequence and the second sequence, none or one or more intermediate sequences each consisting of RRRRRR or RQRQR are included. Further, of the first sequence, the second sequence and the intermediate sequences, two or more neutral amino acids are included between any two sequences adjacent to each other.

Abstract: The present embodiment provides a compound represented by the formula (1): Q-CHR2??(1) (Q is a nitrogen-containing aliphatic group containing two or more tertiary nitrogens but no oxygen, and R is an aliphatic group containing a biodegradable group). From the compound in combination with other lipids such as a lipid capable of reducing aggregation, lipid particles can be formed. Further, the compound can be used for a pharmaceutical composition to deliver an activator into cells.